Epizyme Inc (EPZM) is Palo Alto Investors LP’s 8th Largest Position
Palo Alto Investors LP raised its stake in Epizyme Inc (NASDAQ:EPZM) by 0.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,895,075 shares of the biopharmaceutical company’s stock after buying an additional 34,232 shares during the quarter. Epizyme accounts for about 5.2% of Palo Alto Investors LP’s portfolio, making the stock its 8th largest position. Palo Alto Investors LP owned approximately 9.92% of Epizyme worth $122,388,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently added to or reduced their stakes in EPZM. Quantbot Technologies LP acquired a new stake in shares of Epizyme during the first quarter worth about $111,000. Principal Financial Group Inc. acquired a new stake in shares of Epizyme during the first quarter worth about $187,000. Teacher Retirement System of Texas acquired a new stake in shares of Epizyme during the fourth quarter worth about $202,000. Element Capital Management LLC acquired a new stake in shares of Epizyme during the first quarter worth about $207,000. Finally, Bailard Inc. acquired a new stake in shares of Epizyme during the fourth quarter worth about $251,000. 85.22% of the stock is currently owned by hedge funds and other institutional investors.
Epizyme opened at $15.80 on Thursday, Marketbeat Ratings reports. The stock has a market cap of $1.12 billion, a P/E ratio of -7.25 and a beta of 2.09. Epizyme Inc has a 52-week low of $9.30 and a 52-week high of $21.40.
EPZM has been the topic of a number of research analyst reports. Wedbush raised their price target on Epizyme from $20.00 to $25.00 in a research report on Friday, May 18th. Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a research report on Thursday, March 15th. BidaskClub raised Epizyme from a “hold” rating to a “buy” rating in a research report on Thursday, March 15th. SunTrust Banks reaffirmed a “buy” rating and set a $27.00 price target on shares of Epizyme in a research report on Wednesday, March 14th. Finally, Leerink Swann set a $24.00 price target on Epizyme and gave the stock a “buy” rating in a research report on Tuesday, April 24th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $22.92.
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.